Prospector Partners LLC bought a new stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 112,966 shares of the company's stock, valued at approximately $7,737,000. Prospector Partners LLC owned 0.09% of Henry Schein as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in Henry Schein by 6.5% during the first quarter. JPMorgan Chase & Co. now owns 6,373,036 shares of the company's stock worth $436,489,000 after purchasing an additional 390,399 shares during the period. Palestra Capital Management LLC bought a new stake in Henry Schein during the fourth quarter worth about $182,988,000. Dimensional Fund Advisors LP lifted its position in Henry Schein by 4.8% during the first quarter. Dimensional Fund Advisors LP now owns 2,240,933 shares of the company's stock worth $153,480,000 after purchasing an additional 103,384 shares during the period. Burgundy Asset Management Ltd. lifted its position in Henry Schein by 33.9% during the first quarter. Burgundy Asset Management Ltd. now owns 2,235,429 shares of the company's stock worth $153,105,000 after purchasing an additional 566,530 shares during the period. Finally, Steadfast Capital Management LP lifted its position in Henry Schein by 254.2% during the fourth quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company's stock worth $113,336,000 after purchasing an additional 1,175,408 shares during the period. Institutional investors own 96.62% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on HSIC. UBS Group cut their price objective on shares of Henry Schein from $75.00 to $70.00 and set a "neutral" rating for the company in a research report on Wednesday, August 6th. Evercore ISI lowered their target price on Henry Schein from $78.00 to $70.00 and set an "in-line" rating for the company in a research note on Wednesday, August 6th. JPMorgan Chase & Co. lowered their target price on Henry Schein from $80.00 to $76.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Baird R W downgraded Henry Schein from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 14th. Finally, Wells Fargo & Company lowered their target price on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $75.58.
Get Our Latest Report on HSIC
Henry Schein Stock Performance
Henry Schein stock opened at $67.84 on Monday. The business has a 50 day moving average of $70.81 and a 200-day moving average of $70.72. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $82.49. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The company has a market capitalization of $8.23 billion, a P/E ratio of 21.88, a P/E/G ratio of 2.24 and a beta of 0.81.
Henry Schein (NASDAQ:HSIC - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The firm had revenue of $3.24 billion during the quarter, compared to analyst estimates of $3.22 billion. During the same period in the prior year, the company earned $1.23 EPS. The business's quarterly revenue was up 3.3% compared to the same quarter last year. On average, equities research analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current year.
Henry Schein Profile
(
Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Read More
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.